Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure

• Published in: European journal of clinical investigation 2003-08, Vol.33 (8), p.648-656
• Main Authors: Altieri, P., Brunelli, C., Garibaldi, S., Nicolino, A., Ubaldi, S., Spallarossa, P., Olivotti, L., Rossettin, P., Barsotti, A., Ghigliotti, G.
• Format: Article
• Language: English
• Subjects: Aged; Biological and medical sciences; Cardiac Output, Low - blood; Cardiology. Vascular system; Enzyme-Linked Immunosorbent Assay - methods; Extracellular matrix; Extracellular Matrix - metabolism; Heart; heart failure; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Male; Matrix Metalloproteinase 2 - blood; Matrix Metalloproteinase 9 - blood; Medical sciences; Middle Aged; MMP-2; MMP-9; Protease Inhibitors - blood; remodeling; Tissue Inhibitor of Metalloproteinase-1 - blood; Tissue Inhibitor of Metalloproteinase-2 - blood; Tissue Inhibitor of Metalloproteinases - blood
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1046/j.1365-2362.2003.01187.x

Background Progression of heart failure is associated with interstitial changes in the heart and in areas distant from the heart. Enhanced expression of metalloproteinases 2 and 9 and of metalloproteinases tissue inhibitors 1 and 2 have been found in ventricular tissue of patients with heart failure. Our aim was to determine whether increased activity of metalloproteinase‐2, metalloproteinase‐9 and of metalloproteinases tissue inhibitor‐1 and metalloproteinases tissue inhibitor‐2 were also present in plasma of patients with heart failure. Design Levels of metalloproteinase‐2, metalloproteinase‐9 and of metalloproteinase tissue inhibitor‐1 and metalloproteinases tissue inhibitor‐2 were measured in venous blood of 51 patients with heart failure, and were compared with levels of 52 control subjects. Samples collected from patients and control subjects were assayed for gelatinolytic activity (zymography) and for protein levels. Results Compared with the control subjects, the patients with heart failure had a significant increase in activity levels (mean ± SE, ng mL−1) of prometalloproteinase‐9 (95·1 ± 11·2 and 38·9 ± 4·5*), activ. metalloproteinase‐9 (18·4 ± 2·5 and 10·9 ± 1·3*), and of prometalloproteinase‐2 (571·4 ± 26·1 and 456·8 ± 21·1*) (respectively: patients and control sub jects; *P